Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Propafenone blocks human cardiac Kir2.x channels by decreasing the negative electrostatic charge in the cytoplasmic pore.
Amorós I, Dolz-Gaitón P, Gómez R, Matamoros M, Barana A, de la Fuente MG, Núñez M, Pérez-Hernández M, Moraleda I, Gálvez E, Iriepa I, Tamargo J, Caballero R, Delpón E. Amorós I, et al. Among authors: moraleda i. Biochem Pharmacol. 2013 Jul 15;86(2):267-78. doi: 10.1016/j.bcp.2013.04.023. Epub 2013 May 3. Biochem Pharmacol. 2013. PMID: 23648307
Flecainide increases Kir2.1 currents by interacting with cysteine 311, decreasing the polyamine-induced rectification.
Caballero R, Dolz-Gaitón P, Gómez R, Amorós I, Barana A, González de la Fuente M, Osuna L, Duarte J, López-Izquierdo A, Moraleda I, Gálvez E, Sánchez-Chapula JA, Tamargo J, Delpón E. Caballero R, et al. Among authors: moraleda i. Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15631-6. doi: 10.1073/pnas.1004021107. Epub 2010 Aug 16. Proc Natl Acad Sci U S A. 2010. PMID: 20713726 Free PMC article.
Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.
Samadi A, de los Ríos C, Bolea I, Chioua M, Iriepa I, Moraleda I, Bartolini M, Andrisano V, Gálvez E, Valderas C, Unzeta M, Marco-Contelles J. Samadi A, et al. Among authors: moraleda i. Eur J Med Chem. 2012 Jun;52:251-62. doi: 10.1016/j.ejmech.2012.03.022. Epub 2012 Mar 30. Eur J Med Chem. 2012. PMID: 22503231
Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease.
Samadi A, Chioua M, Bolea I, de Los Ríos C, Iriepa I, Moraleda I, Bastida A, Esteban G, Unzeta M, Gálvez E, Marco-Contelles J. Samadi A, et al. Among authors: moraleda i. Eur J Med Chem. 2011 Sep;46(9):4665-8. doi: 10.1016/j.ejmech.2011.05.048. Epub 2011 May 26. Eur J Med Chem. 2011. PMID: 21669479
Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
Wang L, Esteban G, Ojima M, Bautista-Aguilera OM, Inokuchi T, Moraleda I, Iriepa I, Samadi A, Youdim MB, Romero A, Soriano E, Herrero R, Fernández Fernández AP, Ricardo-Martínez-Murillo, Marco-Contelles J, Unzeta M. Wang L, et al. Among authors: moraleda i. Eur J Med Chem. 2014 Jun 10;80:543-61. doi: 10.1016/j.ejmech.2014.04.078. Epub 2014 Apr 29. Eur J Med Chem. 2014. PMID: 24813882
Potent anticholinesterasic and neuroprotective pyranotacrines as inhibitors of beta-amyloid aggregation, oxidative stress and tau-phosphorylation for Alzheimer's disease.
García-Font N, Hayour H, Belfaitah A, Pedraz J, Moraleda I, Iriepa I, Bouraiou A, Chioua M, Marco-Contelles J, Oset-Gasque MJ. García-Font N, et al. Among authors: moraleda i. Eur J Med Chem. 2016 Aug 8;118:178-92. doi: 10.1016/j.ejmech.2016.04.023. Epub 2016 Apr 11. Eur J Med Chem. 2016. PMID: 27128182
41 results